Filovirus therapy
AssigneesThe Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of Oxford
InventorsMiles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.
Claims19
A composition comprising ovine polyclonal antibodies in a form suitable for administration in treating, suppressing or preventing Ebola virus disease in a patient, wherein said antibodies bind to Ebola virus glycoprotein, wherein said ovine polyclonal antibodies are raised against a recombinant Ebola virus glycoprotein, and wherein said recombinant Ebola virus glycoprotein lacks the endogenous transmembrane domain.
A method of treating, suppressing or preventing Ebola virus disease in a patient, said method comprising administering to a patient an antibody composition comprising ovine polyclonal antibodies, wherein said polyclonal antibodies bind to Ebola virus glycoprotein, and wherein said polyclonal antibodies do not substantially bind to the endogenous transmembrane domain of Ebola virus glycoprotein, and wherein said ovine polyclonal antibodies are raised against recombinant Ebola virus glycoprotein, wherein said recombinant Ebola virus glycoprotein lacks the endogenous transmembrane domain.
Dependencies are inferred from the claim text.